The gamma chain gene of the interleukin-2 receptor (IL2RG) is the disease gene for X-linked severe combined immunodeficiency (XSCID). This gene defect occurs in 1 in 10,000 to 100,000 births and affects males, though females can carry the defect and pass it to their sons. Males with XSCID generally die of infections in the first year of life unless they are rescued by bone marrow transplantation. New mutations account for a substantial proportion of cases. Detection of IL2RG mutations in XSCID males allows: i) definition of clinical features and long-term follow-up of XSCID; ii) study of specific mutations with regard to frequency and clinical severity; iii) study of functional characteristics of defective gamma chain protein encoded by mutated IL2RG from XSCID patients; iv) participation in the evolving management of SCID families, including devising and performing carrier and prenatal testing; v) examining psychologic impact of XSCID on families and their utilization of genetic services; and vi) planning new therapeutic approaches. A worldwide database of mutations created here, IL2RGbase, currently lists over 200 independent mutations. Prenatal testing of at-risk pregnancies has allowed for implementation of neonatal bone marrow transplantation and utero transplantation. Our pool of XSCID affected subjects with proven mutations will allow us to choose and have access to appropriate subsets of XSCID patients likely to benefit from retroviral gene therapy. - Genetics, Immunology, Infect, Pediatric Research, Perinatal Period, Transplantation - Human Subjects & Human Subjects: Interview, Questionaires, or Surveys Only
| Chan, Kee; Puck, Jennifer M (2005) Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol 115:391-8 |
| Chinen, Javier; Puck, Jennifer M (2004) Perspectives of gene therapy for primary immunodeficiencies. Curr Opin Allergy Clin Immunol 4:523-7 |
| Chinen, Javier; Puck, Jennifer M (2004) Successes and risks of gene therapy in primary immunodeficiencies. J Allergy Clin Immunol 113:595-603; quiz 604 |
| Hale, Laura P; Buckley, Rebecca H; Puck, Jennifer M et al. (2004) Abnormal development of thymic dendritic and epithelial cells in human X-linked severe combined immunodeficiency. Clin Immunol 110:63-70 |
| Notarangelo, Luigi; Casanova, Jean-Laurent; Fischer, Alain et al. (2004) Primary immunodeficiency diseases: an update. J Allergy Clin Immunol 114:677-87 |
| Matsuzaki, Hajime; Loi, Halina; Dong, Shoulian et al. (2004) Parallel genotyping of over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array. Genome Res 14:414-25 |
| Cooper, Max D; Lanier, Lewis L; Conley, Mary Ellen et al. (2003) Immunodeficiency disorders. Hematology Am Soc Hematol Educ Program :314-30 |
| Myers, Laurie A; Patel, Dhavalkumar D; Puck, Jennifer M et al. (2002) Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 99:872-8 |
| Vihinen, M; Arredondo-Vega, F X; Casanova, J L et al. (2001) Primary immunodeficiency mutation databases. Adv Genet 43:103-88 |
| Fanos, J H; Davis, J; Puck, J M (2001) Sib understanding of genetics and attitudes toward carrier testing for X-linked severe combined immunodeficiency. Am J Med Genet 98:46-56 |
Showing the most recent 10 out of 11 publications
